<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Haemophilus influenzae type b conjugate vaccine (Hib): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Haemophilus influenzae type b conjugate vaccine (Hib): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Haemophilus influenzae type b conjugate vaccine (Hib): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8511" href="/d/html/8511.html" rel="external">see "Haemophilus influenzae type b conjugate vaccine (Hib): Drug information"</a> and <a class="drug drug_patient" data-topicid="11752" href="/d/html/11752.html" rel="external">see "Haemophilus influenzae type b conjugate vaccine (Hib): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F178251"><span class="drugH1">Brand Names: US</span>
<ul>
<li>ActHIB;</li>
<li>Hiberix;</li>
<li>PedvaxHIB</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52911912"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ActHIB</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1059142"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Vaccine</span>;</li>
<li>
<span class="list-set-name">Vaccine, Inactivated Bacteria</span></li></ul></div>
<div class="block dop drugH1Div" id="F178258"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization</b>
<b>: Note:</b> Preterm infants should be vaccinated according to their chronological age, beginning at 2 months of age; number of doses for completion of Hib series dependent upon products including some combination formulations (3 doses: ActHIB, Hiberix; 2 doses: PedvaxHIB) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24572654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24572654'])">Ref</a></span>) (see combination product monographs for specific dosing information)</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 6 weeks to 6 months: Minimum age for first dose is 6 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">ActHIB, Hiberix (PRP-T): IM: 0.5 mL per dose for a total of 3 doses administered as follows: 2, 4, and 6 months of age</p>
<p style="text-indent:-2em;margin-left:6em;">PedvaxHIB (PRP-OMP): IM: 0.5 mL per dose for a total of 2 doses administered as follows: 2 and 4 months of age</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3186cf6-f751-4742-9832-a3acba1abdd9">Booster immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Booster immunization:</b> ACIP recommendation: ActHIB, Hiberix, PedvaxHIB: Children 12 to 15 months: IM: 0.5 mL as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24572654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24572654'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="030231b8-f8a7-4a85-8830-e75f8b3f4505">Catch-up immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Catch-up immunization:</b>
<b>Note:</b> Do not restart the series. If doses have been given, refer to current immunization guidelines for specific schedule and timing of dose based on patient age and previous number of doses.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children 4 to 59 months: IM: 0.5 mL per dose for a total of 1 to 4 doses:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents; unimmunized <b>and</b> are at increased risk for invasive Hib disease due to anatomic/functional asplenia or splenectomy, HIV infection, immunoglobulin deficiency, early component complement deficiency, or chemotherapy or radiation therapy: IM: 0.5 mL as a single dose; may use any of the Hib conjugate vaccines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24572654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24572654'])">Ref</a></span>). Unimmunized defined as persons who have not received a primary series and booster dose or at least 1 dose of a Hib vaccine after 14 months of age.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d70f3993-5d4a-4c84-9f75-1cb5e97c6ff8">Repeat immunization for high-risk conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Repeat immunization for high-risk conditions</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24572654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24572654'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Invasive Hib disease: Infants and Children &lt;24 months: Revaccinate with a second primary series beginning 4 weeks after onset of disease</p>
<p style="text-indent:-2em;margin-left:4em;">Undergoing chemotherapy or radiation therapy: Infants and Children &lt;60 months: If dose administered within 14 days of starting or given during therapy: Repeat the doses at least 3 months after therapy completion</p>
<p style="text-indent:-2em;margin-left:4em;">Hematopoietic stem cell transplant recipient: Children and Adolescents: Revaccinate with a 3-dose regimen beginning 6 to 12 months after successful transplant, regardless of vaccination history. Doses should be administered ≥4 weeks apart.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112869"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51112870"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F13361407"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8511" href="/d/html/8511.html" rel="external">see "Haemophilus influenzae type b conjugate vaccine (Hib): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b0ff740-7382-4ae5-b8d5-5afdc2c4ea24">Prevention of invasive disease caused by <i>Haemophilus influenzae</i> type b</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of invasive disease caused by </b>
<i>
<b>Haemophilus influenzae</b></i>
<b> type b (Hib):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May use any of the Hib conjugate vaccines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24572654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24572654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adults who have not received the childhood Hib series <b>and</b> are at increased risk for invasive Hib disease due to sickle cell disease, anatomic/functional asplenia, or splenectomy:</i>
<b>IM: </b>One dose (0.5 mL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24572654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24572654'])">Ref</a></span>). For patients undergoing elective splenectomy, consider administering the dose at least 14 days prior to the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24572654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24572654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adults who are recipients of a successful hematopoietic stem cell transplant:</i>
<b>IM: </b>Revaccinate with a 3-dose regimen (0.5 mL/dose) beginning 6 to 12 months after the transplant, regardless of vaccination history. Doses should be administered ≥4 weeks apart (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24572654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24572654'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990527"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987836"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F178228"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for infants and children, unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (6% to 29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (≤30%), pain at injection site (41% to 49%), swelling at injection site (2% to 19%), tenderness at injection site (children: ≤20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (infants: 49% to 60%; children: 13% to 39%), irritability (infants: 67% to 70%; children: 13% to 58%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (infants: &gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Induration at injection site (children: ≤6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (children)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Fussiness in an infant or toddler, restlessness</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema, nonimmune anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Abscess at injection site (sterile), swelling of injected limb (extensive)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Febrile seizure, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Hypotonic/hyporesponsive episode</p></div>
<div class="block coi drugH1Div" id="F178241"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to <i>Haemophilus</i> b polysaccharide, tetanus toxoid-containing vaccine (Hiberix and ActHIB only), or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F178225"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis or tendinopathy) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Guillain-Barré syndrome (GBS): ActHIB, Hiberix: Use with caution in patients with history of GBS; carefully consider risks and benefits to vaccination in patients known to have experienced GBS within 6 weeks following previous tetanus-containing vaccination.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tetanus immunization: Immunization with ActHIB or Hiberix does not substitute for routine tetanus immunization.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or nonlive) for which a person is eligible at a single medical visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. According to the ACIP, monovalent Hib vaccines are interchangeable; however, if different brands are used in the primary series and the number of doses required for series completion varies, then the higher number of doses is recommended for series completion (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Postpone vaccination during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]) if appropriate; may have a reduced response to vaccination (ACIP [Kroger 2023]). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines). Nonlive vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; nonlive vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (AAP [Saari 2003]; ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Some products may contain lactose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Packaging may contain natural latex rubber.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2023]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the annual ACIP Recommended Immunization Schedules (refer to CDC schedule for detailed information). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions are available from the IDSA (Rubin 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]).</p></div>
<div class="block foc drugH1Div" id="F178235"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution:</p>
<p style="text-indent:-2em;margin-left:4em;">Hiberix: <i>Haemophilus</i> b capsular polysaccharide 10 mcg [bound to tetanus toxoid 25 mcg] per 0.5 mL</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">ActHIB: <i>Haemophilus</i> b capsular polysaccharide 10 mcg [bound to tetanus toxoid 24 mcg] per 0.5 mL [contains formaldehyde; may be reconstituted with provided diluent (forms solution)]</p>
<p style="text-indent:-2em;margin-left:4em;">Hiberix: <i>Haemophilus</i> b capsular polysaccharide 10 mcg [bound to tetanus toxoid 25 mcg] per 0.5 mL [contains lactose 12.6 mg] [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, suspension:</p>
<p style="text-indent:-2em;margin-left:4em;">PedvaxHIB: <i>Haemophilus</i> b capsular polysaccharide 7.5 mcg [bound to <i>Neisseria meningitidis</i> OMPC 125 mcg] per 0.5 mL (0.5 mL) [contains aluminum; natural rubber/natural latex in packaging]</p></div>
<div class="block geq drugH1Div" id="F178221"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323178"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Hiberix Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mcg (per each): $15.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Pedvax HIB Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mcg/0.5 mL (per 0.5 mL): $35.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F58268114"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Act-HIB: <i>Haemophilus</i> b 10 mcg [bound to tetanus protein 18 mcg-30 mcg] per 0.5 mL</p></div>
<div class="block adip drugH1Div" id="F53567000"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">The conjugate vaccines currently available consist of <i>Haemophilus influenzae</i> type b (Hib) capsular polysaccharide (also referred to as PRP) linked to a carrier protein. PedvaxHIB (PRP-OMP) is linked to the outer membrane protein complex from <i>Neisseria meningitidis</i>. ActHIB and Hiberix (PRP-T) use tetanus toxoid conjugate as the carrier protein.</p></div>
<div class="block admp drugH1Div" id="F52612958"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IM: Shake well prior to administration; must be administered within 24 hours of reconstitution. Administer IM into midlateral aspect of the thigh in infants and small children; administer in the deltoid area to older children and adults; not for IV or SubQ administration. If injecting in the deltoid muscle, use proper injection technique (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, adolescents should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:0em;margin-top:2em;">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) should be used for the vaccination and firm pressure on the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F178238"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> For IM administration; do not inject IV, intradermally, or subcutaneously. Shake well prior to use. Administer into the anterolateral thigh or deltoid. If injecting in the deltoid muscle, use proper injection technique (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Do not administer into buttocks due to potential risk of injury to sciatic nerve. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, patients should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F178249"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">ActHIB: Store lyophilized powder and diluent under refrigeration at 2°C to 8°C (36°F to 46°F); do not freeze. If not used immediately after reconstitution, may store under refrigeration for up to 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Hiberix: Prior to reconstitution, store powder under refrigeration at 2°C to 8°C (36°F to 46°F). Protect from light. Diluent may be stored under refrigeration or at room temperature; do not freeze, discard diluent if frozen. If not used immediately after reconstitution, may store under refrigeration for up to 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">PedvaxHIB: Store under refrigeration at 2°C to 8°C (36°F to 46°F); do not freeze.</p></div>
<div class="block meg drugH1Div" id="F25734115"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">In the United States, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient/caregiver before administering each dose of this vaccine; the VIS edition date and date it was provided to the patient/caregiver should be recorded as required by US law; VIS is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Fhib.html&amp;token=mjmpv7xMHRIW2nr%2B3NCnsUZAizKE5q1N5Y6YVyHCDVdnyLqA1hHjDCLQugB0t1TFg6m6umAEqL0gl8X5zAMhYQ%3D%3D&amp;TOPIC_ID=12933" target="_blank">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hib.html</a>.</p></div>
<div class="block usep drugH1Div" id="F53567171"><span class="drugH1">Use</span>
<p style="text-indent:0em;">Routine, full series immunization of children 6 weeks to 5 years of age against invasive disease caused by <i>H. influenzae</i> (ActHIB: FDA approved in ages 2 months to 5 years; Hiberix: FDA approved in ages 6 weeks to &lt;5 years; PedvaxHIB: FDA approved in ages 2 to 71 months)</p>
<p style="text-indent:0em;margin-top:2em;">The Advisory Committee on Immunization Practices (ACIP) recommends vaccination for the following  (CDC/ACIP [Briere 2014]):</p>
<p style="text-indent:-2em;margin-left:4em;">• Routine immunization in all infants and children through 59 months</p>
<p style="text-indent:-2em;margin-left:4em;">• Unimmunized* children 12 through 59 months including chemotherapy recipients, anatomic or functional asplenia (including sickle cell disease), HIV infection, immunoglobulin deficiency, or early component complement deficiency</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">Efficacy data are not available for use in older children and adults with chronic conditions associated with an increased risk of Hib disease; however, may be used in certain situations:</p>
<p style="text-indent:-2em;margin-left:6em;">• Unimmunized* children ≥5 years, adolescents, and adults with anatomic or functional asplenia (including sickle cell disease)</p>
<p style="text-indent:-2em;margin-left:6em;">• Unimmunized* children ≥5 years and adolescents with HIV infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Children &lt;5 years undergoing chemotherapy or radiation treatment</p>
<p style="text-indent:-2em;margin-left:6em;">• Successful hematopoietic stem cell transplant recipients</p>
<p style="text-indent:-2em;margin-left:6em;">• Children ≥15 months and adolescents undergoing elective splenectomy</p>
<p style="text-indent:-2em;margin-left:4em;">* Unimmunized is defined as persons who have not received a primary series and booster dose or at least 1 dose of a Hib vaccine after 14 months of age</p></div>
<div class="block mst drugH1Div" id="F49748540"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Hib (<i>haemophilus</i> b conjugate vaccine) may be confused with HepB (hepatitis B vaccine).</p>
<p style="text-indent:-2em;margin-left:4em;">Hib (<i>haemophilus</i> b conjugate vaccine) may be confused with HPV (human papillomavirus vaccine; 2vHPV, HPV2, 4vHPV, HPV4, or 9vHPV are the correct abbreviations).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299433"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F178229"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of cladribine when possible. Patients vaccinated less than 14 days before initiating or during cladribine should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to methotrexate initiation, if possible. If patients are vaccinated less than 14 days prior to or during methotrexate therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F178244"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Nonlive bacterial vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2023]).</p></div>
<div class="block mopp drugH1Div" id="F53567134"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for hypersensitivity and syncope for 15 minutes following administration (ACIP [Kroger 2023]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F178224"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates production of anticapsular antibodies and provides active immunity to <i>Haemophilus influenzae</i> type b. Vaccination provides protective antibodies in &gt;95% of infants who are vaccinated with a 2- or 3-dose series (CDC 2012). An anti-PRP concentration of ≥1.0 mcg/mL predicts long-term protection.</p></div>
<div class="block phk drugH1Div" id="F25306341"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Immunity develops progressively with each dose. Immunity can be inferred ~ 2 weeks after the initial series is complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Antibody concentrations exceeding 0.15 mcg/mL correlate with clinical protection from disease. Antibody concentrations exceeding 1 mcg/mL correlate with prolonged protection from disease, generally implying several years of protection.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F178245"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Hiberix</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(BO)</span> <span class="country">Bolivia, Plurinational State of</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Vacina haemophilus influenzae b (conjugada)</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix | Quimi hib</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Hiberix</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hibest</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix vakcina</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Biohib | HiBE | Hiberix | Peda hib | Sii Hibpro</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Acthib</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Hiberix</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Euhib | Hiberix</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Hiberix | Hibest</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Omnihib</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Haemophilus Influenzae Type B Conjugate Vaccine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix | Quimi hib</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Act hib</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Act hib | Hiberix</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ActHIB.1">
<a name="ActHIB.1"></a>ActHIB (<i>Haemophilus</i> b conjugate vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ActHIB.2">
<a name="ActHIB.2"></a>Act-HIB (<i>Haemophilus</i> b conjugate vaccine) [product monograph]. Toronto, Ontario, Canada: Sanofi Pasteur Limited; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24572654">
<a name="24572654"></a>Briere EC, Rubin L, Moro P, Cohn A, Clark T, Messonnier N; Division of Bacterial Diseases; National Center for Immunization and Respiratory Diseases; CDC. Prevention and control of <i>Haemophilus influenzae</i> type b disease; recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2014;63(RR-01):1-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-hib-pediatric-drug-information/abstract-text/24572654/pubmed" id="24572654" target="_blank">24572654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed., second printing. Washington DC: Public Health Foundation, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19763078">
<a name="19763078"></a>Centers for Disease Control and Prevention (CDC). Licensure of a <i>Haemophilus influenzae</i> type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. <i>MMWR Morb Mortal Wkly Rep</i>. 2009;58(36):1008-1009. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a5.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a5.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-hib-pediatric-drug-information/abstract-text/19763078/pubmed" id="19763078" target="_blank">19763078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-hib-pediatric-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc</i> (2003). 2013;53(1):102-103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-hib-pediatric-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Hiberix (<i>Haemophilus</i> B conjugate vaccine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Updated 2023. Accessed April 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PedvaxHIB.1">
<a name="PedvaxHIB.1"></a>PedvaxHIB (Haemophilus B conjugate vaccine) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20478932">
<a name="20478932"></a>Pisacane A, Continisio P, Palma O, et al, "Breastfeeding and Risk for Fever After Immunization," <i>Pediatrics</i>, 2010, 125(6):e1448-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-hib-pediatric-drug-information/abstract-text/20478932/pubmed" id="20478932" target="_blank">20478932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al, “Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,” <i>Lancet</i>, 2009, 374(9698):1339-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-hib-pediatric-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-hib-pediatric-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12837889">
<a name="12837889"></a>Saari TN; American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. <i>Pediatrics</i>. 2003;112(1, pt 1):193-198. doi:10.1542/peds.112.1.193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haemophilus-influenzae-type-b-conjugate-vaccine-hib-pediatric-drug-information/abstract-text/12837889/pubmed" id="12837889" target="_blank">12837889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Published March 26, 2020. Available at https://apps.who.int/iris/handle/10665/331590
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 12933 Version 180.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
